Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
A webcast of the presentation will be available in the Investor Relations section of the company's website at www.clementiapharma.com. A replay of the webcast will be available for 30 days following the presentation.
Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases. For more information, please visit www.clementiapharma.com.
THRUST Investor Relations
Source: Clementia Pharmaceuticals Inc.